Bio Historical Cash Flow
| TECH Stock | USD 51.26 1.95 3.66% |
Analysis of Bio Techne cash flow over time is an excellent tool to project Bio Techne Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 47.5 M or Depreciation of 115.4 M as it is a great indicator of Bio Techne ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bio Techne Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Techne Corp is a good buy for the upcoming year.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. About Bio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bio's non-liquid assets can be easily converted into cash.
Bio Techne Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Bio Techne Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bio Techne operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Bio Techne's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bio Techne Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. As of now, Bio Techne's Other Cashflows From Financing Activities is increasing as compared to previous years. The Bio Techne's current Depreciation is estimated to increase to about 115.4 M, while Sale Purchase Of Stock is forecasted to increase to (261.9 M).
Bio Techne cash flow statement Correlations
Click cells to compare fundamentals
Bio Techne Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Techne cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (43.2M) | (161.0M) | (19.6M) | (80.0M) | (275.7M) | (261.9M) | |
| Change To Inventory | (7.1M) | (32.0M) | 400K | (14.2M) | (18.1M) | (17.2M) | |
| Change In Cash | 52.5M | (26.5M) | 8.0M | (28.8M) | 10.4M | 10.9M | |
| Free Cash Flow | 307.9M | 280.4M | 216.1M | 236.1M | 256.6M | 269.4M | |
| Change In Working Capital | 29.3M | (69.5M) | (48.2M) | (10.1M) | 11.5M | 12.1M | |
| Begin Period Cash Flow | 146.6M | 199.1M | 172.6M | 180.6M | 151.8M | 89.3M | |
| Total Cashflows From Investing Activities | (243.5M) | (96.9M) | (265.6M) | (203.0M) | (35.2M) | (36.9M) | |
| Other Cashflows From Financing Activities | (19.3M) | 143.8M | 92.5M | 39.1M | 45.2M | 47.5M | |
| Depreciation | 87.7M | 101.1M | 107.2M | 111.7M | 109.9M | 115.4M | |
| Other Non Cash Items | 74.0M | (18.4M) | (99.8M) | 30.7M | 103.0M | 108.1M | |
| Capital Expenditures | 44.3M | 44.9M | 38.2M | 62.9M | 31.0M | 18.3M | |
| Total Cash From Operating Activities | 352.2M | 325.3M | 254.4M | 299.0M | 287.6M | 301.9M | |
| Net Income | 139.6M | 263.1M | 285.4M | 168.1M | 73.4M | 89.2M | |
| Total Cash From Financing Activities | (62.6M) | (242.9M) | 22.6M | (122.4M) | (253.9M) | (241.2M) | |
| End Period Cash Flow | 199.1M | 172.6M | 180.6M | 151.8M | 162.2M | 94.2M | |
| Other Cashflows From Investing Activities | (225.9M) | (51.9M) | (28.0M) | 7.0M | 9.7M | 10.2M | |
| Stock Based Compensation | 49.0M | 42.2M | 39.2M | 38.0M | 40.8M | 42.9M | |
| Change To Netincome | 43.8M | 94.7M | (47.8M) | (37.2M) | (42.8M) | (40.6M) | |
| Dividends Paid | 49.6M | 50.2M | 50.3M | 50.4M | 50.4M | 50.1M | |
| Change To Account Receivables | (15.5M) | (57.6M) | (20.9M) | (20.5M) | 42.6M | 44.7M | |
| Investments | (243.5M) | (96.9M) | (265.6M) | (203.0M) | (35.2M) | (36.9M) | |
| Change Receivables | 6.6M | (15.5M) | (57.6M) | (20.9M) | (18.8M) | (19.7M) | |
| Cash And Cash Equivalents Changes | 48.5M | 46.1M | (14.4M) | 11.4M | 13.1M | 8.3M | |
| Cash Flows Other Operating | (148.0M) | 72.2M | (39.1M) | (15.1M) | (13.6M) | (12.9M) | |
| Change To Liabilities | 5.7M | 19.1M | 12.7M | (35.0M) | (31.5M) | (29.9M) | |
| Net Borrowings | (148.5M) | (15.5M) | (85.5M) | 94M | 84.6M | 88.8M | |
| Change To Operating Activities | (53K) | 19.4M | 4.7M | (29.1M) | (26.2M) | (24.9M) |
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Dividend Share 0.32 | Earnings Share 0.46 | Revenue Per Share | Quarterly Revenue Growth 0.036 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.